Actively Recruiting
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2025-05-28
411
Participants Needed
1
Research Sites
559 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Early triple negative breast cancer patients who do not achieve pathologic complete response after neoadjuvant chemotherapy with or without immunotherapy have bad prognosis. ctDNA effectively identified patients with highest relapse risk. This trial aims to explore whether the combination of anlotinib, immunotherapy and capecitabine could improve the outcome of this subgroup of high relapse risk patients compared with investigator's choice of therapy.
CONDITIONS
Official Title
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Stage II or III breast cancer patients, excluding occult, inflammatory, and metaplasia breast cancer
- Triple negative breast cancer (TNBC) defined as estrogen receptor (ER) <= 10%, progesterone receptor (PR) <=10%, HER 0-1+, or HER2 2+ with negative FISH
- Female patients aged 18 to 70 years
You will not qualify if you...
- No specific exclusion criteria listed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen Memorial Hospital
Guangzhou, Guangodng, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here